Twitter | Search | |
OncoAlert
🌐 Worldwide Network of Oncology Professionals with the common goal of ending cancer, We are !
4,238
Tweets
716
Following
2,548
Followers
Tweets
OncoAlert retweeted
Double Whammy 4h
πŸ‘‡πŸ‘‡πŸ‘‡πŸ‘‡πŸ‘‡πŸ‘‡πŸ‘‡πŸ‘‡πŸ‘‡πŸ‘‡πŸ‘‡πŸ‘‡πŸ‘‡
Reply Retweet Like
OncoAlert retweeted
Axel Grothey 7h
We have now seen several examples where IO agents failed to provide OS benefit when they were tested in randomized trials even in indications where they already had FDA approval based on single-arm studies. Patient selection is key! Who benefits?
Reply Retweet Like
OncoAlert retweeted
Double Whammy 5h
Thank you again for including the patient voice in . Taking down is definitely a team effort.
Reply Retweet Like
OncoAlert retweeted
Paolo Tarantino 2h
Ph3 Checkmate 459 - OS with Nivolumab not superior to Sorafenib in 1st line treatment of adv HCC 🚫 Disappointing, since the relatively low activity of sorafenib. Better patient selection is needed to achieve benefit (PD-L1? TILs? TMB?)
Reply Retweet Like
OncoAlert retweeted
IJGC 1h
Reply Retweet Like
OncoAlert retweeted
Andres Cervantes 46m
The Legacy project, a joint effort of 11 institutions accross the Atlantic, to improve outcomes of gastric cancer patients has got a national recognition in Madrid
Reply Retweet Like
OncoAlert retweeted
Double Whammy 45m
Thanks again for creating these easy to understand infographics showing common sites (including weirdo sites). Early stagers don't always know what to watch for post-Tx.
Reply Retweet Like
OncoAlert retweeted
JTO 1h
In the latest JTO Editor’s choice, LizΓ©e and colleagues analyze the β€œCost Effectiveness of Web-Based Patient-Reported Outcome Surveillance in Lung Cancer Patients.” Discover the findings here:
Reply Retweet Like
OncoAlert retweeted
ONS 2h
Our very own kept busy this weekend at , who all got to see her in action?
Reply Retweet Like
OncoAlert retweeted
Marina Garassino 3h
I voted! Remember to do it!
Reply Retweet Like
OncoAlert retweeted
Nathan A. Pennell MD, PhD 5h
Please support my upcoming VeloSano ride July 20, 2019. 100% of the proceeds go directly to cancer research!
Reply Retweet Like
OncoAlert 4h
Replying to @double_whammied
Perfect! That just happens to be our passion :-) great mind always find great company !!
Reply Retweet Like
OncoAlert retweeted
Al-Ola A Abdallah MD Jun 18
Chimeric Antigen Receptor (CAR) T-Cell Therapy | Oncology | JAMA Oncology | JAMA Network ⁦⁩ ⁦⁩ ⁦⁩
Reply Retweet Like
OncoAlert retweeted
Skip Burris 9h
Great line-up of speakers β€” latest updates on the novel approaches from experts.
Reply Retweet Like
OncoAlert 8h
Reply Retweet Like
OncoAlert 8h
Reply Retweet Like
OncoAlert 8h
Reply Retweet Like
OncoAlert 8h
Reply Retweet Like
OncoAlert 8h
Reply Retweet Like
OncoAlert 8h
Who is ? We're Oncology professionals, who formed this network w/1 mission: Fight cancer through social media by disseminating potentially Practice Changing knowledge( )Worldwide, so YOU ARE !
Reply Retweet Like